Press Releases
-
Advanced Biodesign Announces First Patient Dosed in ODYSSEY
Lyon (France), March 4, 2025 – Advanced BioDesign, a clinical-stage pharmaceutical company specializing in the development of new therapeutic approaches to resistant cancers, is pleased…
-
Advanced BioDesign is nominee as « Best StartUp » for 2024 Prix Galien USA
Advanced Biodesign has been nominated as the “Best Start-Up” at the prestigious Prix Galien USA 2024! 🏆 This nomination is a testament to our unwavering commitment to innovation and…
-
Advanced BioDesign accelerates ODYSSEY clinical trial with a new design following ABD-3001’s highly promising initial results in Acute Myeloid Leukemia
• Initial clinical data for ABD-3001 in AML have led French health authorities to approve a compassionate use program for the treatment. • Thanks to…
-
Advanced BioDesign: A new study published in the Journal of Cellular Molecular Medicine on the involvement of ALDH activity in r/r AML
Lyon (France), October 29, 2024 – Acute Myeloid Leukemia (AML) remains a major medical challenge despite recent advances in targeted molecular therapies. A recent study…
Advanced BioDesign 